Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clofazimine

FDA-approved product (capsule, oral), marketed as Lamprene.

Registered studies
50+
Lab records
5
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Clofazimine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Leprosy

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Drugs for treatment of lepra
FDA pharmacologic class
Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04BA01; FDA class Antimycobacterial

Repurposing investigation

Clofazimine is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli30.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis78.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 5 of 5 lab records
Open Clofazimine in ChEMBL Registered studies below
Show the 5 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clofazimine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.

    NCT00000641

    Registered record
    Registry ID
    NCT00000641
    Conditions
    Mycobacterium Avium-intracellulare Infection; HIV Infections
    Interventions
    Ciprofloxacin hydrochloride; Ethambutol hydrochloride; Amikacin sulfate; Azithromycin; Rifampin; Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1994-12
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Avium-intracellulare Infection; HIV Infections
    InterventionCiprofloxacin hydrochloride; Ethambutol hydrochloride; Amikacin sulfate; Azithromycin +2 more
    PhasePhase 2
    Registry statusCompleted

  • Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS

    NCT00001047

    Registered record
    Registry ID
    NCT00001047
    Conditions
    Mycobacterium Avium-intracellulare Infection; HIV Infections
    Interventions
    Ethambutol hydrochloride; Clarithromycin; Clofazimine; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1996-08
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Avium-intracellulare Infection; HIV Infections
    InterventionEthambutol hydrochloride; Clarithromycin; Clofazimine; Rifabutin
    PhasePhase 3
    Registry statusCompleted

  • A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS

    NCT00001058

    Registered record
    Registry ID
    NCT00001058
    Conditions
    Mycobacterium Avium-intracellulare Infection; HIV Infections
    Interventions
    Indinavir sulfate; Ritonavir; Ethambutol hydrochloride; Clarithromycin; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1999-01
    Enrolment
    246

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Avium-intracellulare Infection; HIV Infections
    InterventionIndinavir sulfate; Ritonavir; Ethambutol hydrochloride; Clarithromycin +1 more
    PhasePhase 2
    Registry statusCompleted

  • A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease

    NCT00002058

    Registered record
    Registry ID
    NCT00002058
    Conditions
    Mycobacterium Avium-intracellulare Infection; HIV Infections
    Interventions
    Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Avium-intracellulare Infection; HIV Infections
    InterventionClofazimine
    PhaseNot applicable
    Registry statusCompleted

  • Lamprene Multiple Patient Program

    NCT04334070

    Registered record
    Registry ID
    NCT04334070
    Conditions
    Non-Tuberculous Mycobacterial (NTM) Infections
    Interventions
    Lamprene®/Clofazimine
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Tuberculous Mycobacterial (NTM) Infections
    InterventionLamprene®/Clofazimine
    PhaseNot recorded
    Registry statusAvailable